Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

NCT00082381 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

551

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Exenatide (AC2993)
DRUG: Insulin glargine

Sponsor

AstraZeneca

Collaborators

[object Object]